Pharmacyclics Gets “Refuse To File” Letter On Xcytrin
This article was originally published in The Pink Sheet Daily
Executive Summary
Company had hoped for priority review when it submitted its NDA for treatment of brain metastases from non-small cell lung cancer in December.